ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SPRY ARS Pharmaceuticals Inc

8.26
-0.24 (-2.82%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 334,679
Bid Price 8.00
Ask Price 8.98
News -
Day High 8.545

Low
2.55

52 Week Range

High
11.27

Day Low 8.155
Share Name Share Symbol Market Stock Type
ARS Pharmaceuticals Inc SPRY NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.24 -2.82% 8.26 19:00:00
Open Price Low Price High Price Close Price Previous Close
8.46 8.155 8.545 8.26 8.50
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
5,242 334,679 US$ 8.27 US$ 2,767,656 - 2.55 - 11.27
Last Trade Type Quantity Price Currency
16:56:36 6 US$ 8.30 USD

ARS Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 797.10M - - - -14.66
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

ARS Pharmaceuticals News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SPRY Message Board. Create One! See More Posts on SPRY Message Board See More Message Board Posts

Historical SPRY Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week9.289.288.1458.53539,558-1.02-10.99%
1 Month10.1311.278.1459.36637,897-1.87-18.46%
3 Months6.2111.276.138.76721,4562.0533.01%
6 Months3.4011.273.386.99594,3124.86142.94%
1 Year6.4811.272.556.401,035,8211.7827.47%
3 Years5.2811.272.556.49788,3182.9856.44%
5 Years5.2811.272.556.49788,3182.9856.44%

ARS Pharmaceuticals Description

ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.

Your Recent History

Delayed Upgrade Clock